Last reviewed · How we verify
SER120 1500 ng — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
SER120 1500 ng (SER120 1500 ng) — Serenity Pharmaceuticals, Inc.. SER120 is an investigational therapeutic agent in Phase 3 development by Serenity Pharmaceuticals with an undisclosed mechanism of action.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SER120 1500 ng TARGET | SER120 1500 ng | Serenity Pharmaceuticals, Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SER120 1500 ng CI watch — RSS
- SER120 1500 ng CI watch — Atom
- SER120 1500 ng CI watch — JSON
- SER120 1500 ng alone — RSS
Cite this brief
Drug Landscape (2026). SER120 1500 ng — Competitive Intelligence Brief. https://druglandscape.com/ci/ser120-1500-ng. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing